technIQ software for Corindus CorPath GRX surgical robot receives FDA approval

Listen to this article

Corindus Inc., which develops precision vascular robotics, today announced the launch of a new set of automated robotic movements in the technIQ Series designed for its CorPath GRX System. The Waltham, Mass.-based company has received 510(k) clearance from the U.S. Food and Drug Administration for the software automation, which provides predictable and consistent movements to aid in advanced device manipulation during complex coronary and peripheral procedures.

Corindus, a Siemens Healthineers company, said its CorPath is designed to bring robotic precision to percutaneous coronary and vascular procedures. It said CorPath GRX includes upgrades to increase precision, improve workflow, and extend the capabilities and range of surgical procedures that can be performed robotically.

technIQ automates skilled movements

Jean Fajadet, M.D., the co-director of interventional cardiology at Clinique Pasteur in Toulouse, France, performed the first in-human coronary procedures with the benefit of the new automated movements, which replicate manual techniques of highly skilled interventionalists. The procedures demonstrated how the new movements can help to reduce procedure time associated with wire and device manipulation. Corindus added that technIQ can help standardize the quality of care by offering advanced techniques to all physicians.

“This new software algorithm gives the operator new possibilities to advance and facilitate treatment, especially with complex lesions,” said Fajadet. “I am pleased with the success of using the automated moves and am honored to play a role in the advancement of robotic technology that will make interventional procedures more efficient and safer for our patients.”

Robot-assisted surgery evolves

In 2018, Corindus received CE Mark and FDA clearance for an automated technique called Rotate on Retract (RoR). RoR was the first automated robotic movement in the technIQ Series and has demonstrated the potential to significantly reduce wiring time, said the company.

The latest global introduction and FDA clearance for the technIQ Series provides physicians with four additional automated robotic movements that aid with complex tasks such as crossing lesions, navigating tortuosity, and precisely measuring the anatomy for appropriate device size selection.

“The new technIQ movements mark the next phase in the evolution of robotic-assisted intervention and a vital step toward the advancement of our technology,” said Wayne Markowitz, executive vice president and head of Corindus. “Automating more movements used in cardiovascular intervention will allow physicians to focus their attention on overall case strategy while equipping them with advanced techniques for navigating the vasculature.”